Anti-PD1 medicines, which are a kind of immunotherapy, have demonstrated potential in glioma preclinical research (Reardon et al., 2016; Kim et al., 2017); however, the majority of clinical trials have not achieved the anticipated levels of effectiveness (Caccese et al., 2019). This evidence concerns the gene PDCD1 and glioma.